Low HDL-C: a secondary target of dyslipidemia therapy

Area of Science:

• Cardiology
• Lipidology
• Pharmacology

Background:

• Current coronary heart disease (CHD) prevention guidelines prioritize lowering low-density lipoprotein cholesterol (LDL-C).
• Increasing evidence suggests high-density lipoprotein cholesterol (HDL-C) is a significant secondary target for CHD risk reduction.
• Epidemiological data and clinical trials link low HDL-C levels to increased CHD event risk.

Purpose of the Study:

• To explore the role of high-density lipoprotein cholesterol (HDL-C) as a secondary therapeutic target in coronary heart disease (CHD) prevention.
• To evaluate the potential of raising HDL-C levels to further reduce CHD risk beyond LDL-C lowering.
• To review current and emerging therapeutic strategies for modifying HDL-C levels.

Main Methods:

• Review of epidemiological data and large-scale clinical trials involving lipid-modifying therapies.
• Analysis of the impact of statins, fibrates, and niacin on HDL-C levels.
• Examination of novel therapeutic approaches, including HDL mimetics and cholesteryl ester transfer protein inhibitors.

Main Results:

• Low HDL-C levels are consistently associated with higher CHD risk.
• Statins improve HDL-C, but the extent varies; combination therapy with fibrates or niacin enhances HDL-C more but may increase adverse effects.
• New therapies targeting HDL-C are under development.

Conclusions:

• While LDL-C remains the primary target, therapies that effectively lower LDL-C and raise HDL-C may offer superior CHD risk reduction.
• Targeting HDL-C presents a promising avenue for further mitigating cardiovascular risk.
• Future dyslipidemia management may involve dual-action therapies for comprehensive CHD prevention.